News | September 10, 2008

New MI Application Accelerates Pancreatic Cancer Detection

September 10, 2008 - Cellvizio in vivo cellular imaging technology is helping researchers detect early-stage pancreatic cancer, understand stem cell development and enhance the value of whole body imaging, according to three new animal studies being presented at the World Molecular Imaging Congress in Nice, France, held September 10-13, 2008.

According to results from two recently published studies on Cellvizio imaging of pancreatic cancer, the targeted molecular imaging approach and vascular monitoring method developed, respectively, by Ken Young Lin and colleagues at the Center for Molecular Imaging Research in Boston and Johannes von Burstin and colleagues at the Technical University of Munich.

The Cellvizio system, by Mauna Kea Technologies, provides microscopic visualization of mucosal tissue and improves clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. The growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques.

These methods promise to substantially increase the detection rates of early-stage pancreatic cancer. Because early diagnosis and therapy response evaluation are the prerequisite for curative surgery, the presented translational results offer the prospect of improving overall survival of pancreatic cancer patients. The first study was published in the July 2008 issue of Translational Oncology and the second appeared in the August 15 issue of International Journal of Cancer.

A promising technique for in vivo tracking of somatic stem cells and could lead to valuable insights for improving the success of bone marrow transplants.Daniel Lewandowski and colleagues from the French Atomic Energy Commission in Fontenay aux roses, France, demonstrated that with Cellvizio they were able to view live in vivo the cellular dynamics of somatic stem cell development without interfering in the process.

The connection between cancer and blot clots may also be clearer for researchers. Using Cellvizio, Grace Thomas and colleagues from the Center of Research in Biological Oncology and Oncopharmacology in Marseille, France, demonstrated that the development of a cancerous tumor directly influences kinetics of blood clot formation in vivo. Through in vivo cellular imaging of platelets and leukocytes with Cellvizio, they were able to observe that times to blockage of veins and arteries were all significantly reduced in mice developing a tumor in comparison with those observed in control mice. These results may provide insights on how to prevent the risk of blood clot complications associated with cancer.

Carine Pestourie and colleagues from the French Atomic Energy Commission in France showed that the combination of whole body imaging systems such as Positron Emission Tomography (PET) and Cellvizio provides a new tool to monitor quantitatively and dynamically the in vivo distribution of compounds, such as Quantum Dots, from whole body to cellular scales with low invasiveness. Such a combination could be used in the future to better diagnose human pathologies.

For more information: www.cellvizio.com

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Overlay Init